Lymphocyte‐monocyte ratio (LMR) can predict bendamustine therapeutic efficacy in low‐grade B‐cell lymphoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lymphocyte‐monocyte ratio (LMR) can predict bendamustine therapeutic efficacy in low‐grade B‐cell lymphoma
Authors
Keywords
-
Journal
International Journal of Laboratory Hematology
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-04-28
DOI
10.1111/ijlh.13216
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Useful prognostic tools based on complete blood cell counts in diffuse large B‐cell lymphoma
- (2019) Joji Shimono et al. International Journal of Laboratory Hematology
- Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
- (2018) Franck Morschhauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study
- (2018) Tadeusz Robak et al. LANCET ONCOLOGY
- Tumor-associated macrophages: implications in cancer immunotherapy
- (2017) Amy J Petty et al. Immunotherapy
- Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
- (2017) Robert Marcus et al. NEW ENGLAND JOURNAL OF MEDICINE
- Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project
- (2016) A. M. Perry et al. HAEMATOLOGICA
- Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial
- (2016) Laurie H Sehn et al. LANCET ONCOLOGY
- Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project
- (2016) A. M. Perry et al. HAEMATOLOGICA
- Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib
- (2015) J. C. Byrd et al. BLOOD
- Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study
- (2015) Laurie H. Sehn et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma
- (2015) John G. Gribben et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of a lymphocyte to monocyte ratio in stage IV colorectal cancer
- (2015) Tsuyoshi Ozawa et al. JOURNAL OF SURGICAL RESEARCH
- Prognostic value of pre-operative inflammatory response biomarkers in gastric cancer patients and the construction of a predictive model
- (2015) Qiwen Deng et al. Journal of Translational Medicine
- Sustained CD4 and CD8 lymphopenia after rituximab maintenance therapy following bendamustine and rituximab combination therapy for lymphoma
- (2015) Tsutsumi Yutaka et al. LEUKEMIA & LYMPHOMA
- Baseline and Trend of Lymphocyte-to-Monocyte Ratio as Prognostic Factors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Patients Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
- (2015) Yu-Mu Chen et al. PLoS One
- Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
- (2014) I. W. Flinn et al. BLOOD
- Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma
- (2014) Luis F. Porrata et al. LEUKEMIA & LYMPHOMA
- The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy
- (2013) Alessandro Rambaldi et al. AMERICAN JOURNAL OF HEMATOLOGY
- Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era
- (2013) Reina Watanabe et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- 90Yttrium-Ibritumomab Tiuxetan Consolidation of First Remission in Advanced-Stage Follicular Non-Hodgkin Lymphoma: Updated Results After a Median Follow-Up of 7.3 Years From the International, Randomized, Phase III First-Line Indolent Trial
- (2013) Franck Morschhauser et al. JOURNAL OF CLINICAL ONCOLOGY
- Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
- (2013) Mathias J Rummel et al. LANCET
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- (2013) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunosuppressive CD14+HLA-DRlow/- monocytes in B-cell non-Hodgkin lymphoma
- (2010) Y. Lin et al. BLOOD
- Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
- (2010) Gilles Salles et al. LANCET
- Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents
- (2008) L. M. Leoni et al. CLINICAL CANCER RESEARCH
- Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma
- (2008) Franck Morschhauser et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started